Evoke Pharma and QOL Medical Announce Expiration of Tender Offer

Company Overview - Evoke Pharma, Inc. is a specialty pharmaceutical company focused on developing drugs for gastrointestinal (GI) disorders and diseases, notably GIMOTI, a nasal spray formulation of metoclopramide for diabetic gastroparesis [5][6] - QOL Medical, LLC is a specialty biopharmaceutical company dedicated to providing solutions for rare diseases, emphasizing the acquisition and commercialization of orphan and gastrointestinal products [4] Merger and Acquisition Details - QOL Medical's subsidiary, QOL-EOS Merger Sub, Inc., successfully completed a tender offer to acquire all outstanding shares of Evoke for $11.00 per share, with the offer expiring on December 15, 2025 [1][2] - Approximately 1,164,862 shares, representing about 67.63% of Evoke's outstanding shares, were validly tendered in the offer [2] - Following the merger, Evoke became a wholly owned subsidiary of QOL Medical, and its shares ceased trading on Nasdaq, with plans for delisting and deregistration under the Securities Exchange Act of 1934 [3]